Local cytokine concentrations are required for inhibition of tumor growth with less toxic side-effects. However, genetically engineered tumor cells secreting cytokines still induce toxicity and activate bystander cells. To circumvent such problems, membrane-bound forms of IL-4 (IL-4m) were expressed on MethA fibrosarcoma tumor cells. Chimeric forms of IL-4 with the type I transmembrane protein CD4 or type II transmembrane protein TNF were designed to express IL-4 in opposite orientations on the tumor cell surface. The IL-4m on tumor clones was able to support cell growth of the IL-4 dependent cytotoxic cell line (CT.4S) and
Introduction
Strategies to enhance antitumor immunity by genetic modification of tumor cells have been used in animal models and clinical studies. Several cytokines provide direct or indirect accessory signals that are of importance in T lymphocyte activation. 1, 2 While repeated exposure to low doses of cytokines in the tumor site have resulted in a strong antitumor immune response, 3, 4 the usual limitation is toxicity. [5] [6] [7] Transfected cells secreting cytokines such as GM-CSF, IL-2, IL-4, IFN␥ or IL-12 have been used as vaccines to induce antitumor responses in mice. [8] [9] [10] [11] [12] However, toxicity of transduced cells and of the released cytokines, [13] [14] [15] bystander T cell activation or expansion and differentiation of T cells without apparent specificity for the tumor antigen has been observed. [16] [17] [18] In animal models, even though there are CTLs that kill tumor cells they are not specific for the tumor cells. 3, 10, 19, 20 In mice, IL-2-induced and IL-4-induced expansion of T lymphocytes is not causally related to tumor shrinkage. 21, 22 In general, T cell expansion can occur without significant tumor destruction, although the reduction of an immunogenic tumor may help in the activation of systemic immunity.
Several cytokines are expressed as membrane-associated forms, soluble forms or proteolytically processed forms; IL-1, 23 TNF, 24 LT␣, 25 and IFN␥. 26 Genetically engineered membrane-bound forms can result in lower tox- icity of TNF and LT␣. 24, 25 In some cases cytokines secreted by the tumor cells bind to receptors on the tumor cells and deliver effective signals by cell to cell contact. 27, 28 In the present study, we have generated transfected tumor cells expressing a membrane-bound form of IL-4 (IL-4m). If the tumor cells display the proper tumorassociated antigen (TAA)/MHC complex (signal 1) and a costimulatory signal (signal 2), efficient direct CTL activation may occur. Therefore, effective expression of IL4m on tumor cells may serve as a sufficient costimulatory signal to activate CTL to provide antitumor immunity. This strategy should also alleviate problems of toxicity encountered with soluble cytokines. [5] [6] [7] [13] [14] [15] 
Results
In order to focus antitumor immunity and reduce bystander cell activation, we transfected cells with membrane-associated forms of IL-4 and compared them with cells expressing secreted IL-4. Two different forms of chimeric proteins were generated: one with CD4, a type I transmembrane protein and the other with TNF, a type II transmembrane protein (Figure 1 ). MethA tumor cells were then transfected with expression constructs and individual clones expressing secreted IL-4 (IL-4s), IL-4/CD4 and IL-4/TNF were isolated. All clones including empty vector controls had similar morphology and in vitro growth properties.
The expression of IL-4m is stable on tumor cells Expression of IL-4m on transfected MethA cells was analyzed by FACS staining using the 11B11 mAb (Figure 2 ). The expression of IL-4/CD4 was also confirmed by staining with the anti-CD4 mAb GK1.5 (data not shown). Expression of secreted IL-4 by the IL-4s clones was measured by a proliferation assay using the IL-4 dependent CT.4S cell line. The levels of expression were high and comparable to the TLX-IL-4 transfectant. 29 All transfectants expressed very similar levels of H-2L d , and another cell surface antigen Sca-1 that was also similar to the parental MethA cells (data not shown). 
Discussion
IL-4 is a multifunctional lymphokine produced by the Th2 and also involved in the generation of CTL. [30] [31] [32] Of several cytokines whose presence affects tumor growth, IL-4 appears to be very potent. Tumor cells secreting a substantial amount of IL-4 are unable to form tumors and induce systemic immunity. 8 The IL-4-activated tumor inhibition is a consequence of the macrophage and eosinophil infiltration. 8, 22, 33, 34 Host T cells are also involved in the induction and effector phase of IL-4-activated tumor rejection with the antigen non-specific cells predominating. 4, 8, 22 In this study we have demonstrated that the membrane-bound versions of IL-4 expressed on tumor cells are biologically functional. The IL-4/TNF tumor clone supported the growth of 2C CTL, spleen cells from 2C TCR transgenic mice, and Th2 cells in vitro, and induced a long-term antitumor immunity. The tumor cells transfected with IL-4 gene and releasing large amount of IL-4 are unable to form tumors. The IL-4/CD4 clone showed downregulated tumorigenicity as previously reported, 35 but the IL-4/TNF clone failed to form tumor even at a higher inoculation dose (1 × 10 7 cells per mouse). Even after drug selection and cloning, it has been demonstrated that the tumor clones become heterogeneous in expression of transfected cytokine gene, 35 so that the proportion of the cells actively expressing transgene may affect the tumorigenicity of transfectants.
Lymphocytes require two signals to become actiGene Therapy (36) vated. [36] [37] [38] [39] [40] The interaction between an antigen-specific TCR on T lymphocytes and antigenic peptide/MHC complexes on APCs such as tumor cells or macrophages generates signal 1. Signal 2 is delivered through antigen non-specific receptors on T cells. Without costimulation, exposure of T cells to antigen causes unresponsiveness or anergy. 38 Induction of anergy is prevented by providing IL-2 or crosslinking the IL-2 receptor, 39, 40 and tumors with appropriate costimulation such as CD80 or CD86 effectively induce an antitumor immune response. 41 The TAA peptides associated with MHC class I and the IL4m molecules on tumor cells were expected to function as signal 1 and 2, respectively. This mode of T cell activation may lead to specific activation of circulating CTL probably via cell to cell contact, and may help avoid massive nonspecific inflammatory cell infiltration and activation. In addition, efficient B cell activation may occur, if the TAA is expressed on cell surfaces and provides epitopes to BCR. Importantly, the IL-4m on tumor cells may also lead to TAA-specific B cell stimulation without involving T cell help. The precise effector mechanism responsible for IL-4m-induced antitumor effect remains to be studied.
Figure 3 Proliferation of T cell clones in response to

cells subcutaneously in right thigh flank and tumor growth monitored. Tumors formed in all the mice (six mice) injected with MethA cells (squares), and in three out of six mice injected with IL-4/CD4(15) clone (circles). The mice injected with IL4s(36) (triangles) or IL-4/TNF(61) (inverted triangles) were tumor free. The average diameter of the tumor ± s.d. is shown. The tumor growth in the three mice out of six mice injected with IL-4s
Other investigators have observed cell surface-associated cytokines on cytokine secreting cells, 27, 28, 42 providing further support for the contention that secreted cytokines may form a functional surface reservoir on the secreting cell. The immunologic importance of the cell-associated cytokines is largely unknown. On the other hand, IL-1, 23 TNF, 24 LT␣ 25 and IFN␥ 26 are expressed in two different versions, one is a membrane-bound form and the other is soluble form. While precise functional discrimination of the forms has not been made, the membrane-bound form of TNF has a unique function distinct from that of the soluble TNF. 43, 44 The limited expression and range of delivery of cytokine would be critical for therapeutic purposes to avoid bystander activation. For example, while the induction of systemic toxicity due to septic shock and cachexia is the major limiting factor preventing clinical use of TNF, 7 tumor cells expressing membrane-bound form of TNF induced antitumor immunity with low toxicity. 45 As an analogy to our study, engineered GM-CSF as membrane-bound form was generated to induce antitumor immunity. 46 The target of their study was to stimulate dendritic cells, which is clearly different from our target, to stimulate cytotoxic T lymphocytes. The strategy to express a soluble cytokine as membrane-bound form, especially the cytokines driving antigen-specific lymphocyte differentiation and activation, would be applicable to the therapeutic purposes for viral infection as well as tumor.
Materials and methods
Mice
Female BALB/c and C57BL/6 mice, 6 to 8 weeks old, were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and the Korea Research Institute of Chemical Technology (Taejon, Korea). The 2C TCR transgenic mice were provided by Dr D Loh (Washington University Medical School, St Louis, MO, USA).
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Cell culture and antibodies The methylcholanthrene-induced fibrosarcoma MethA (BALB/c origin) was maintained in vitro in RPMI-1640 medium supplemented with 10% FBS and antibiotics and occasionally in vivo passage. D10, 48 A.E7, 49 and Clone 19 50 cells have been described previously. An IL-2-dependent murine cytotoxic cell line CTLL-2 and its IL-4-dependent variant CT.4S 51 were obtained from Dr Charles Janeway Jr (Yale University, CT, USA), and maintained in Click's EHAA medium supplemented with 10% FBS and IL-4 (100 U/ml) or IL-2 (10 U/ml), respectively. IL-2 and IL-4 were provided in the form of culture supernatants from transfected cells that secreted these cytokines. 29 mAb to IL-4 (11B11, rat IgG1) was kindly provided by Dr Charles Janeway jr and mAbs to MHC class I specific to L d (28-14-8S and 30-5-7S) were obtained from Dr Peter Cresswell (Yale University). The anti-Sca-1 antibody (E13 161-7) recognizes Ly-6A/E.
Plasmid construction and transfection
The cDNA of mouse IL-4 was purchased from American Type Culture Collection (ATCC; Rockville, MD, USA). The cDNA of mouse CD4 was obtained from Dr SoonCheol Hong (Medical College of Ohio, OH, USA) and the cDNA of mouse TNF was obtained from Dr Sang-Young Chun (Chonnam National University, Korea). To construct IL-4/CD4 chimeric cDNA, primers specific for IL-4 (forward: 5ЈCGC GAA TTC ATG GGT CTC AAC CCC3Ј, reverse: 5ЈGCG CCA TGG CGA GTA ATC CAT TTG3Ј) and CD4 (forward: 5ЈGCG CCA TGG AAG ACG CTG GTG CTG GGG AAG3Ј, reverse: 5ЈCGC GAA TTC TCA GAT GAG ATT ATG GCT CTT3Ј) were used to amplify the respective cDNA fragments by PCR (Figure 1 ). To generate IL-4/TNF chimeric cDNA, primers specific for IL-4 (forward: 5ЈCG CGA ATT CAT ATC CAC GGA TGC3Ј, reverse: 5ЈGCG CGG ATC CTA CGA GTA ATC3Ј) and TNF (forward: 5ЈGC GGA TCC ATG AGC ACA GAA3Ј, reverse: 5ЈC GCG AAT TCC TCC GGC CAT AGA ACT3Ј) were used to amplify the respective cDNA fragments. The 370 bp IL-4 fragment and 240 bp TNF fragment encoding transmembrane and cytoplasmic regions were obtained and cloned in pNeoSR␣II expression vector. All the PCR was performed with capillary PCR machine (FTC-2000, Taehan Medical Co, Korea) and the structure of the chimeric DNAs was confirmed by DNA sequence analysis.
For electroporation, MethA cells were harvested and washed twice in HBSS (137 mm NaCl, 5 mm KCl, 0.7 mm H 3 PO 4 , 6 mm dextrose, 20 mm HEPES, pH 7.0) (Gibco-BRL, Grand Island, NY, USA). The cells (2 × 10 7 cells) were resuspended in HBSS and mixed with 20 g plasmid DNA. After incubation on ice for 10 min, they were electroporated at 320 V, 960 F (BioRad, Hercules, CA, USA) and transferred to normal medium. After 48 h, cells were plated in 96-well plates in (1 g/l) G418 containing medium. The drug resistant colonies were usually visible after 2-3 weeks.
Assay of IL-4 activity
Transfected cell lines were assayed for IL-4 activity by measuring proliferation of the CT.4S cell line. 51 Briefly, H-thymidine (Amersham, Piscataway, NJ, USA) per well, and samples were collected using a PHD cell harvestor (Skatron, Norway). 3 H-thymidine incorporation was used as an index of DNA synthesis with results expressed as a mean c.p.m. per culture.
Proliferation assay of T lymphocyte clones and spleen cells from 2C transgenic mouse The proliferation of the T cell clones (D10, A.E7, Clone 19, CTLL-2) cultured together with IL-4 expressing MethA clones was measured by 3 H-thymidine incorporation as described above. The spleen cells from 2C TCR transgenic mouse were prepared and mixed cell cultures with X-ray irradiated MethA clones were established and proliferation assessed as described above.
Measurement of IL-4m expression by FACS analysis
The transfected clones were first incubated for 30 min at 4°C with primary antibody appropriately diluted in staining buffer (1× PBS containing 0.02% sodium azide and 2% FBS). Cells were washed and incubated for an additional 30 min at 4°C with FITC-goat anti-mouse IgG antibody (Cappel, Durham, NC, USA) or FITC-goat antirat IgG antibody (Hyclone, Logan, UT, USA). Expression of IL-4/CD4 was confirmed by using anti-CD4 antibody (GK1.5) and FITC-goat anti-rat IgG antibody. The stained cells were analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
Tumor challenge
For tumorigenicity studies, mice were inoculated subcutaneously on the right flank with 1 × 10 5 live cells or intraperitoneally with 5 × 10 6 live cells, and tumor growth was measured daily. After initial tumor clone injection, all the mice that rejected tumor clones were rechallenged with wild-type MethA cells, and tumor growth monitored. In the case of subcutaneous injection, tumor size was estimated by measuring the longest surface diameter using a caliper. The mice were killed when they became moribund according to Yale University guidelines.
